- Home
- RMCO vs IGC Comparison
RMCO vs IGC Comparison
Compare RMCO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCO | IGC |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 31.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | RMCO | IGC |
|---|---|---|
| Price | $2.52 | $0.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 10.3K | ★ 991.7K |
| Earning Date | 05-14-2026 | 03-19-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | $209.10 | N/A |
| Revenue Next Year | $133.33 | $13.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.98 | $0.24 |
| 52 Week High | $5.00 | $0.50 |
Technical Indicators
Market Signals| Indicator | RMCO | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 41.03 |
| Support Level | $1.99 | $0.28 |
| Resistance Level | $2.62 | $0.31 |
| Average True Range (ATR) | 0.23 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 9.03 | 15.99 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.